Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!

被引：1

作者：

Al-Jafar, Hassan A. ^{[1
]}

Al-Azmi, Salih ^{[2
]}

Qassem, J. A. ^{[3
]}

Hasan, Eman A. ^{[4
]}

Alduaij, Arwa ^{[5
]}

机构：

[1] Amiri Hosp, Haematol Dept, Kuwait, Kuwait

[2] Amiri Hosp, Resp Dept, Kuwait, Kuwait

[3] Amiri Hosp, Internal Med Dept, Kuwait, Kuwait

[4] Amiri Hosp, Rheumatol Dept, Kuwait, Kuwait

[5] Amiri Hosp, Med Casualty Dept, Kuwait, Kuwait

来源：

CASE REPORTS IN ONCOLOGY | 2012年 / 5卷 / 03期

关键词：

Lenalidomide; Myelodysplastic syndrome; 5q del; Blood transfusion; Remission;

D O I：

10.1159/000345098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelodysplastic syndrome (MDS) refers to a group of haematological, monoclonal disorders. A 50-year-old woman was diagnosed with MDS 5q deletion syndrome [del(5q)], becoming dependent on blood transfusion after long-term treatment with cytotoxic drugs for chronic scleritis. Lenalidomide therapy (10 mg/day) led to profound pancytopaenia, followed by recovery of her blood cell counts. A cytogenetic study, repeated 4 months after lenalidomide treatment, revealed complete remission after only 1 week of lenalidomide therapy. Lenalidomide was approved for low-and intermediate-1-risk MDS, where it normalises platelet counts and induces haematological and cytogenetic remission. This patient has remained transfusion independent for 3 years by continuing on a minimal maintenance dose of lenalidomide. Starting MDS patients on lenalidomide has to be done cautiously or with only 5 mg/day because of the potentially high sensitivity of the stem cells to this immunomodulatory agent in MDS patients.

引用

页码：586 / 591

页数：6

共 10 条

[1]

Cheson, 1997, Oncologist, V2, P28

[2] Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13 [J].